Taliglucerase alfa

(Elelyso®)

Elelyso®

Drug updated on 11/8/2023

Dosage FormInjection (intravenous; 200 units/vial)
Drug ClassHydrolytic lysosomal glucocerebroside-specific enzymes
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of type 1 Gaucher disease in patients 4 years and older with a confirmed diagnosis.

Product Monograph / Prescribing Information

Document TitleYearSource
Elelyso (taliglucerase alfa) Prescribing Information.2023Pfizer Inc., New York, NY

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines

Document TitleYearSource
Recommendations for oral treatment for adult patients with type 1 Gaucher disease.2022Revista Clínica Española